First Time Loading...

Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 270.95 USD 0.59% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies... [ Read More ]

The intrinsic value of one CRL stock under the Base Case scenario is 268.97 USD. Compared to the current market price of 270.95 USD, Charles River Laboratories International Inc is Overvalued by 1%.

Key Points:
CRL Intrinsic Value
Base Case
268.97 USD
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Charles River Laboratories International Inc

Backtest CRL Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CRL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Charles River Labs: Stable 2023, Modest 2024 Growth
2023-Q4 Earnings Call

Charles River Labs: Stable 2023, Modest 2024 Growth

In 2023, Charles River Laboratories showcased its resilient business model, achieving a 6.5% organic revenue growth and an earnings per share (EPS) of $10.67, aligning with the higher end of its forecasts. Despite a broader life sciences downturn, the company generated $4.13 billion in revenue, driven by its Safety Assessment business and growth in the RMS segment. However, operating margins dipped by 130 basis points to 19.1% in Q4, influenced by higher costs and lower Discovery sales, contributing to a 4% annual EPS decline to $10.67. Looking at 2024, constrained spending may persist, yet the firm anticipates stabilization and a flat to 3% organic revenue growth. Non-GAAP EPS projection is $10.90 to $11.40, factoring in a minimum 50 basis-point operating margin expansion.

Financials

Balance Sheet Decomposition
Charles River Laboratories International Inc

Current Assets 1.6B
Cash & Short-Term Investments 276.8m
Receivables 780.4m
Other Current Assets 551.4m
Non-Current Assets 6.6B
Long-Term Investments 243.8m
PP&E 2B
Intangibles 4B
Other Non-Current Assets 349.7m
Current Liabilities 1.1B
Accounts Payable 168.9m
Accrued Liabilities 496m
Other Current Liabilities 390.1m
Non-Current Liabilities 3.5B
Long-Term Debt 2.6B
Other Non-Current Liabilities 895.9m
Efficiency

Earnings Waterfall
Charles River Laboratories International Inc

Revenue
4.1B USD
Cost of Revenue
-2.6B USD
Gross Profit
1.5B USD
Operating Expenses
-869.9m USD
Operating Income
659.3m USD
Other Expenses
-184.7m USD
Net Income
474.6m USD

Free Cash Flow Analysis
Charles River Laboratories International Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CRL Profitability Score
Profitability Due Diligence

Charles River Laboratories International Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive 3-Years Revenue Growth
57/100
Profitability
Score

Charles River Laboratories International Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

CRL Solvency Score
Solvency Due Diligence

Charles River Laboratories International Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
44/100
Solvency
Score

Charles River Laboratories International Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRL Price Targets Summary
Charles River Laboratories International Inc

Wall Street analysts forecast CRL stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRL is 269.35 USD with a low forecast of 237.35 USD and a high forecast of 304.5 USD.

Lowest
Price Target
237.35 USD
12% Downside
Average
Price Target
269.35 USD
1% Downside
Highest
Price Target
304.5 USD
12% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRL Price
Charles River Laboratories International Inc

1M 1M
+7%
6M 6M
+38%
1Y 1Y
+37%
3Y 3Y
-4%
5Y 5Y
+87%
10Y 10Y
+349%
Annual Price Range
270.95
52w Low
164.52
52w High
273.43
Price Metrics
Average Annual Return 18.39%
Standard Deviation of Annual Returns 45.32%
Max Drawdown -64%
Shares Statistics
Market Capitalization 13.9B USD
Shares Outstanding 51 349 800
Percentage of Shares Shorted 3.9%

CRL Return Decomposition
Main factors of price return

What is price return decomposition?

CRL News

Other Videos

Company Profile

Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

13.9B USD

Dividend Yield

0%

Description

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The firm provides research models required in research and development of new drugs, devices, and therapies. The firm's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).

Contact

MASSACHUSETTS
Wilmington
251 Ballardvale St
+17812226000.0
https://www.criver.com/

IPO

2000-06-23

Employees

18 600

Officers

Chairman, CEO & President
Mr. James C. Foster J.D.
Corporate Executive VP & CFO
Ms. Flavia H. Pease
Corporate Executive VP & COO
Ms. Birgit Girshick
Corporate Executive Vice President of Corporate Development & Strategy
Mr. Joseph W. LaPlume
Corporate Executive Vice President of Community Relations
Mr. William D. Barbo
Corporate Senior VP & Chief Accounting Officer
Mr. Michael Gunnar Knell
Show More
Corporate Senior VP & Chief Scientific Officer
Prof. Julie Frearson Ph.D.
Corporate Senior VP & Chief Information Officer
Mr. Mark Mintz
Corporate Vice President of Investor Relations
Todd Spencer
Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. Matthew L. Daniel
Show Less

See Also

Discover More
What is the Intrinsic Value of one CRL stock?

The intrinsic value of one CRL stock under the Base Case scenario is 268.97 USD.

Is CRL stock undervalued or overvalued?

Compared to the current market price of 270.95 USD, Charles River Laboratories International Inc is Overvalued by 1%.